Literature DB >> 7538449

Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner.

S Ozaki1, T Okazaki, K Nakao.   

Abstract

In order to investigate tumoricidal effector cells in therapy by biological response modifiers (BRM) such as Propionibacterium acnes, bacillus Calmette-Guérin (BCG), Streptococcus pyogenes and a protein-bound polysaccharide (PSK), we established T cell lines specific for each BRM from BALB/c mice immunized with the corresponding BRM. These T cell lines proliferated and produced interleukin-2 (IL-2) and/or IL-4, but only in the presence of the relevant BRM and BALB/c spleen cells as the antigen and antigen-presenting cells respectively. Cross-functional experiments indicated that each BRM acts as a nominal antigen, but not as a non-specific immunostimulator. In addition, the T cell lines killed Ia-positive syngeneic B lymphoma cells, but only in the presence of the relevant BRM. These experiments excluded the possibility of cytotoxic effects by each BRM. The T cell lines and clones also killed Ia-negative bystander target cells, but only in the presence of both a relevant antigen and antigen-presenting cells. The T cell clones specific for S. pyogenes or P. acnes tested were Thy1+, L3T4+ and Lyt2-. These results indicate that some BRM exert tumoricidal activity by inducing T cells that recognize them as an antigen and kill tumor cells in an antigen-specific manner. The T cells killed tumor targets in either a tumor-necrosis-factor(TNF)-dependent or a TNF-independent manner. The mediator of the latter pathway remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538449

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  35 in total

1.  Biological response modifier as antigen: OK432-specific T-cell clone as an anti-tumor effector cell.

Authors:  S Ozaki; T Suginoshita
Journal:  Cell Immunol       Date:  1989-05       Impact factor: 4.868

2.  Establishment and characterization of BALB/c lymphoma lines with B cell properties.

Authors:  K J Kim; C Kanellopoulos-Langevin; R M Merwin; D H Sachs; R Asofsky
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

3.  Expression of perforin and membrane-bound lymphotoxin (tumor necrosis factor-beta) in virus-specific CD4+ human cytotoxic T-cell clones.

Authors:  M Yasukawa; Y Yakushijin; H Hasegawa; M Miyake; Y Hitsumoto; S Kimura; N Takeuchi; S Fujita
Journal:  Blood       Date:  1993-03-15       Impact factor: 22.113

4.  Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis.

Authors:  J P Tite; C A Janeway
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

5.  Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.

Authors:  S Y Shu; T Chou; K Sakai
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

6.  Enhancement of T-cell proliferation by PSK.

Authors:  R Hirai; Y Oguchi; N Sugita; K Matsunaga; K Nomoto
Journal:  Int J Immunopharmacol       Date:  1993-08

7.  Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2- T-cells.

Authors:  S Ozaki; T Suginoshita; T Watanabe; H Obayashi
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

Review 8.  Krestin (PSK).

Authors:  S Tsukagoshi; Y Hashimoto; G Fujii; H Kobayashi; K Nomoto; K Orita
Journal:  Cancer Treat Rev       Date:  1984-06       Impact factor: 12.111

9.  Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection.

Authors:  A Nakane; T Minagawa; K Kato
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

10.  Expression of two distinct cytolytic mechanisms among murine CD4 subsets.

Authors:  S T Ju; N H Ruddle; P Strack; M E Dorf; R H DeKruyff
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.